Author:
Nouri Mannan,Ratther Ellca,Stylianou Nataly,Nelson Colleen C.,Hollier Brett G.,Williams Elizabeth D.
Reference89 articles.
1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010
2. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014
3. Phase I/II trial of orteronel (TAK-700) – an investigational 17,20-lyase inhibitor – in patients with metastatic castration-resistant prostate cancer;Dreicer;Clin Cancer Res,2014
4. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509;Joseph;Cancer Discov,2013
5. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer;Rathkopf;J Clin Oncol,2013
Cited by
69 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献